This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


reputable news agency


AACR: Cadonilimab plus chemo beneficial for gastric adenocarcinoma

AACR: cadonilimab plus chemo beneficial for gastric adenocarcinoma

For patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, cadonilimab plus chemotherapy is associated with improved overall survival and progression-free survival, according to a study presented at the annual meeting of the American Association for Cancer Research, held from April 5 to 10 in San Diego.

Jiafu Ji, M.D., Ph.D., from the Gastrointestinal Cancer Center at Peking University Cancer Hospital & Institute in Beijing, and colleagues conducted a randomized, placebo-controlled trial involving adults with untreated, unresectable, locally advanced, or metastatic G/GEJ adenocarcinoma, regardless of PD-L1 expression. Patients from 76 study centers were randomly assigned to cadonilimab plus or placebo plus chemotherapy (305 patients to each group), with a median follow-up of 18.69 months.

The researchers found to be longer in the cadonilimab versus the (15.0 versus 10.8 months; hazard ratio, 0.62). At all prespecified combined positive score cutoffs, overall survival benefits were consistently observed, especially in patients with low PD-L1 expression. The cadonilimab group had longer (median, 7.0 versus 5.3 months; hazard ratio, 0.53). Grade ≥3 treatment-related adverse events occurred in 71.8 and 60.5 percent of patients who received cadonilimab and placebo, respectively; there were no new safety events reported.

"These findings may change the current practice of gastric cancer treatment," Ji said in a statement. "Cadonilimab combined with chemotherapy could become a new standard of care in first-line treatment of gastric cancer, even for patients with low PD-L1 expression."

More information: Press Release

More Information

Copyright © 2024 HealthDay. All rights reserved.

Citation: AACR: Cadonilimab plus chemo beneficial for gastric adenocarcinoma (2024, April 8) retrieved 19 July 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Bispecific immune checkpoint inhibitor improves survival in gastric cancer patients regardless of PD-L1 status


Feedback to editors